Entropy Neurodynamics Limited
ASX: ENP.AX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jason Alan Carroll
- Headquarters
- Camberwell, Australia
- IPO year
- 2025
- Market cap
- A$59.6M
- Website
- https://www.tryptherapeutics.com
Loading ENP…
Loading profile data…Frequently asked questions about ENP
What does Entropy Neurodynamics Limited (ENP.AX) do?
Entropy Neurodynamics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States. The company's lead program candidate is TRP-8803, a formul...
Where does ENP.AX trade?
Entropy Neurodynamics Limited (ENP.AX) trades on the Australian Securities Exchange.
What sector is ENP.AX in?
Entropy Neurodynamics Limited (ENP.AX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Entropy Neurodynamics Limited?
Jason Alan Carroll is the chief executive officer of Entropy Neurodynamics Limited (ENP.AX).
Where is Entropy Neurodynamics Limited headquartered?
Entropy Neurodynamics Limited is headquartered in Australia.
Does ENP.AX pay a dividend?
Entropy Neurodynamics Limited (ENP.AX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ENP.AX go public?
Entropy Neurodynamics Limited (ENP.AX) completed its initial public offering in 2025.